Presidio Partners
VC Fund
San Francisco, United States
Presidio Partners is a VC fund in San Francisco focused on Software and Energy. Previously known as throughout the duration of our investment.They seek to embrace change and creativity to improve outcomes because that is what they believe it will take to successfully tackle the business challenges of the coming decade. Presidio Partners experiments with novel approaches to pharmaceutical development that they believe may increase efficiency. They rethink our portfolio companies’ approaches, and seek to develop new business models where appropriate.The entire Presidio team believes in the power of technology and data to push their entrepreneurs and themselves in ways that will make the world a better place and help us meet ever-changing societal challenges.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 6%
- Fund size:
- $142M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Presidio Partners invests in
SoftwareEnergyHealth CareBiotechnologySaaS
Stages Presidio Partners invests in
Series CFunding RoundSeries BSeries DSeries E
Countries Presidio Partners invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Brodie Cobb
|
|||
Investment Focus
Industry
- Software 4 (22%)
- Energy 3 (17%)
- Health Care 3 (17%)
- Biotechnology 3 (17%)
- SaaS 2 (11%)
Stage
- Series C 5 (28%)
- Funding Round 5 (28%)
- Series B 4 (22%)
- Series D 2 (11%)
- Series E 2 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Brodie Cobb
Founder and CEO
|
Founder and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ESS
|
ESS is a provider of long-duration energy storage solutions ideally suited for C&I, utility, microgrid, and off-grid applications. Since their founding in 2011, ESS has been focused on laying the groundwork for a future powered by clean and reliable energy.With a team that boasts decades of experience in distributed power generation andenergy storage technologies, ESS has developed an extremely cost-effective energy management system that combines a safe, abundant and non-toxic iron-electrolyte with their patented flow cell design. This combination of high performance with low cost means that ESS’s technology is ideally suited for applications that range in size from retail energy management to utility-scale renewables integration. | Series C / Oct 28, 2019 | |
Wildcat Discovery Technologies
|
Wildcat Discovery Technologies accelerates the discovery of new materials for energy applications, with a focus on the development of advanced materials for rechargeable and primary batteries. Wildcat’s business also includes collaborative development projects for materials for other applications, including gas storage, carbon capture,thermoelectrics, and structural materials.Wildcat synthesizes and evaluates thousands of materials every week. To do this, the company uses proprietary unique-in-the-world high throughput synthesis and testing platforms to rapidly explore thousands of new materials with the goal of improving performance and reducing costs.Wildcat employs an experienced team of scientists and engineers, with backgrounds in batteries, materials development, and high throughput automation. We also have a world class scientific advisory board.Wildcat is pursuing partnership and collaboration opportunities with corporate leaders throughout the battery supply chain, including global material suppliers, cell makers, and OEM’s throughout the automotive, electronics, medical, military, and consumer products industries. | $20M / Series C / Oct 18, 2019 | |
Solaria
|
The Solaria Corporation, a solar technology company, manufactures cells and modules for the optics and semiconductor industries. The company develops cell and module technologies that fit into the existing value-add chain. It uses a low-concentration solar PV multiplying technology that produces PV cells from silicon material. | $23M / Jan 11, 2018 | |
|
ESS
|
ESS is a provider of long-duration energy storage solutions ideally suited for C&I, utility, microgrid, and off-grid applications. Since their founding in 2011, ESS has been focused on laying the groundwork for a future powered by clean and reliable energy.With a team that boasts decades of experience in distributed power generation andenergy storage technologies, ESS has developed an extremely cost-effective energy management system that combines a safe, abundant and non-toxic iron-electrolyte with their patented flow cell design. This combination of high performance with low cost means that ESS’s technology is ideally suited for applications that range in size from retail energy management to utility-scale renewables integration. | $13M / Series B / Dec 12, 2017 | |
VYNE Therapeutics
|
VYNE Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chroniccough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor (NK1-R) given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms. Pruritus is the primary patient complaint among atopic dermatitis, psoriasis and prurigo nodularis patients and represents a significant patient need. There are currently no therapies approved in the US that are primarily intended to reduce the pruritus associated with these conditions. We expect data from our ongoing Phase 2 clinical trial in pruritus associated with atopic dermatitis in the 2Q18 and from our ongoing Phase 2 clinical trials in pruritus associated with psoriasis and refractory chronic cough by late 2018 or early 2019. We plan to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the 1H18, with results expected in the 1H20. | $50.5M / Series C / Jul 18, 2017 | |
Mojo Networks
|
The Future of Cloud WiFiAt Mojo Networks, we are leading a revolution in cloud managed WiFi services and products for enterprise wireless. Existing architectures are antiquated. Controllers will soon be obsolete. We make it simple to move your massive enterprise WLAN to the cloud with automation and built-in scaling.Mojo's cloud WiFiplatform is easy to deploy and intuitive to manage while also enabling advanced features like graphical troubleshooting, WiFi user analytics and social engagement. Above all, we continue to advance our widely acknowledged industry-leading security capabilities. We've secured the air and built our cloud designed for a new frontier of prolific connectivity.Prolific – We want seamless connectivity for everyone, everywhere, all the time. Manage your Mojo Networks WiFi products from anywhere in the world – no controllers required.Intuitive – Our access points and sensors are programmed out-of-the-box to automatically discover and connect to the Mojo Networks cloud wireless platform. Deployment and management is a piece of cake.Responsive – Most of the time the Mojo Networks cloud managed WiFi platform works like magic, but when it doesn’t, we respond immediately to do what’s right for our customers.Trustworthy – The credibility of our top-ranked wireless intrusion prevention system (WIPS) is proven every day from the highest levels of government to the infrastructure of developing nations.At Mojo Networks, we are obsessive with making our customers successful. We are committed to fearless creativity and partnering with others who share the same passion. | $30M / Series E / Feb 08, 2017 | |
|
VYNE Therapeutics
|
VYNE Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chroniccough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor (NK1-R) given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms. Pruritus is the primary patient complaint among atopic dermatitis, psoriasis and prurigo nodularis patients and represents a significant patient need. There are currently no therapies approved in the US that are primarily intended to reduce the pruritus associated with these conditions. We expect data from our ongoing Phase 2 clinical trial in pruritus associated with atopic dermatitis in the 2Q18 and from our ongoing Phase 2 clinical trials in pruritus associated with psoriasis and refractory chronic cough by late 2018 or early 2019. We plan to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the 1H18, with results expected in the 1H20. | $45M / Series B / Nov 01, 2015 | |
Cnano Technology
|
Beijing Cnano Technology Co. Ltd. is dedicated to the production of carbon nanotubes and application of advanced energy that includes the application of lithium battery, conductive plastics, and mechanical structures. It is the Chinese branch of the Cnano Company. On the basis of acquiring the exclusive licensing of a patent from TsinghuaUniversity, in combination with its own internal technological innovation, Cnano Technology has developed a large-batch production technology of carbon nano-tubes. Headquartered in Santa Clara, California, USA, Cnano Technology has established advanced research and manufacturing facilities in Beijing, China. | $15M / Series B / Apr 20, 2015 | |
Neos Therapeutics
|
The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs.Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Wortharea. | $20.6M / Feb 19, 2015 | |
BlueStacks
|
BlueStacks is pioneering the next generation of cloud technology for the mobile ecosystem. BlueStacks App Player enables the universe of Android games and apps to run fast and full screen on Windows PCs. App Player is powered by BlueStacks' patented LayerCake virtualization technology and has 145 million users.BlueStacks 2, releasedDecember 3, 2015, users could now run multiple apps at once and navigate between each app in a browser-like tabbed interface.With BlueStacks TV, released April 7, 2016, BlueStacks allows users to stream their gameplay directly to Twitch.tv with one-click. | $12.5M / Series B / Jul 23, 2014 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Energy Investors
25,111 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
FAQ
What does Presidio Partners invest in?
Presidio Partners invests primarily in Software, Energy and Health Care startups, most often at Series C and Funding Round stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Presidio Partners?
Public channels for Presidio Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Presidio Partners?
The team at Presidio Partners includes Brodie Cobb (Founder and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
